
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (30): 3791-3796.DOI: 10.12114/j.issn.1007-9572.2023.0198
Special Issue: 心力衰竭最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2023-02-27
Revised:2023-05-15
Published:2023-10-20
Online:2023-05-31
Contact:
REN Fuxian, GAO Dengfeng
通讯作者:
任付先, 高登峰
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0198
| 组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 住院时间〔M(P25,P75),d〕 | 感染〔例(%)〕 | 糖尿病〔例(%)〕 | 高血压〔例(%)〕 | 慢性阻塞性肺疾病〔例(%)〕 | |
|---|---|---|---|---|---|---|---|---|---|
| 生存组 | 564 | 72.9(64.9,80.5) | 317/247 | 7(5,9) | 191(33.9) | 197(34.9) | 342(60.6) | 52(9.2) | |
| 死亡组 | 19 | 77.8(68.6,81.8) | 11/8 | 2(2,7) | 12(63.2) | 11(57.9) | 12(63.2) | 3(15.8) | |
| Z(χ2)值 | -1.682 | 0.021a | -6.378 | 6.949a | 4.224a | 0.049a | 0.922a | ||
| P值 | 0.092 | 0.884 | 0.059 | 0.008 | 0.040 | 0.825 | 0.337 | ||
| 组别 | 肺循环障碍〔例(%)〕 | 心律失常〔例(%)〕 | 瓣膜病〔例(%)〕 | 周围血管病〔例(%)〕 | 脑血管病〔例(%)〕 | 肾衰竭〔例(%)〕 | 肝病〔例(%)〕 | 肥胖症〔例(%)〕 | 风湿性心脏病〔例(%)〕 |
| 生存组 | 49(8.7) | 253(44.9) | 48 (8.5) | 56 (9.9) | 137(24.3) | 89(15.8) | 23(4.1) | 32(5.7) | 0 |
| 死亡组 | 9(47.4) | 7(36.8) | 2(10.5) | 5(26.3) | 9(47.4) | 9(47.4) | 0 | 1(5.3) | 8(42.1) |
| Z(χ2)值 | 30.697a | 0.487a | 0.094a | 5.268a | 5.164a | 12.990a | 0.808a | 0.082a | 0.273a |
| P值 | <0.001 | 0.485 | 0.760 | 0.022 | 0.023 | <0.001 | 0.369 | 0.775 | 0.601 |
| 组别 | 肺源性心脏病〔例(%)〕 | 冠心病〔例(%)〕 | 心率〔M(P25,P75),次/min〕 | 平均动脉压〔M(P25,P75),mmHg〕 | 呼吸频率〔M(P25,P75),次/min〕 | 体温〔M(P25,P75),℃〕 | |||
| 生存组 | 7(1.2) | 411(72.9) | 86(74,101) | 97(87,110) | 20.00(19.00,22.00) | 36.30(36.20,36.50) | |||
| 死亡组 | 0 | 12(63.2) | 101(95,104) | 106(81,114) | 20.00(20.00,23.50) | 36.20(36.10,36.85) | |||
| Z(χ2)值 | 0.239a | 0.871a | -2.677 | -1.260 | -1.981 | -0.132 | |||
| P值 | 0.625 | 0.351 | 0.007 | 0.208 | 0.048 | 0.895 | |||
| 组别 | 血红蛋白〔M(P25,P75),g/L〕 | 阴离子间隙〔M(P25,P75),mmol/L 〕 | 尿素氮〔M(P25,P75),mmol/L 〕 | 肌酐〔M(P25,P75),μmol/L〕 | 葡萄糖〔M(P25,P75),mmol/L〕 | 钠〔M(P25,P75),mmol/L〕 | |||
| 生存组 | 129.00(113.00,144.00) | 10.20(8.10,11.80) | 7.41(5.54,11.57) | 84.15 (65.50,122.60) | 6.77(5.28, 9.67) | 138.00(135.00,141.00) | |||
| 死亡组 | 98.00 (86.50,124.50) | 15.90(9.70,19.70) | 28.48(9.66,31.38) | 170.50(110.40,277.60) | 9.70(8.08,14.54) | 141.00(137.50,146.50) | |||
| Z(χ2)值 | -3.262 | -3.752 | -4.258 | -3.437 | -1.404 | -1.073 | |||
| P值 | 0.001 | <0.001 | <0.001 | 0.001 | 0.160 | 0.283 | |||
| 组别 | 钾〔M(P25,P75),mmol/L〕 | 凝血酶原时间〔M(P25,P75),s〕 | 中性粒细胞计数〔M(P25,P75),×109/L〕 | 单核细胞计数〔M(P25,P75),×109/L〕 | 淋巴细胞计数〔M(P25,P75),×109/L〕 | NMLR〔M(P25,P75)〕 | |||
| 生存组 | 3.95(3.57,4.52) | 13.00(11.90,14.30) | 5.52(4.11,7.95) | 0.40(0.37,0.57) | 1.18(0.79,1.66) | 5.00(3.23,8.72) | |||
| 死亡组 | 4.10(3.75,4.41) | 12.90(12.60,16.35) | 6.17(4.34,6.82) | 0.44(0.34,0.62) | 0.89(0.73,1.73) | 8.36(3.15,9.55) | |||
| Z(χ2)值 | -0.933 | -1.641 | -2.860 | -1.369 | -2.005 | -3.089 | |||
| P值 | 0.351 | 0.101 | 0.004 | <0.001 | 0.045 | 0.002 |
Table 1 Compararion of baseline characteristics between the two groups
| 组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 住院时间〔M(P25,P75),d〕 | 感染〔例(%)〕 | 糖尿病〔例(%)〕 | 高血压〔例(%)〕 | 慢性阻塞性肺疾病〔例(%)〕 | |
|---|---|---|---|---|---|---|---|---|---|
| 生存组 | 564 | 72.9(64.9,80.5) | 317/247 | 7(5,9) | 191(33.9) | 197(34.9) | 342(60.6) | 52(9.2) | |
| 死亡组 | 19 | 77.8(68.6,81.8) | 11/8 | 2(2,7) | 12(63.2) | 11(57.9) | 12(63.2) | 3(15.8) | |
| Z(χ2)值 | -1.682 | 0.021a | -6.378 | 6.949a | 4.224a | 0.049a | 0.922a | ||
| P值 | 0.092 | 0.884 | 0.059 | 0.008 | 0.040 | 0.825 | 0.337 | ||
| 组别 | 肺循环障碍〔例(%)〕 | 心律失常〔例(%)〕 | 瓣膜病〔例(%)〕 | 周围血管病〔例(%)〕 | 脑血管病〔例(%)〕 | 肾衰竭〔例(%)〕 | 肝病〔例(%)〕 | 肥胖症〔例(%)〕 | 风湿性心脏病〔例(%)〕 |
| 生存组 | 49(8.7) | 253(44.9) | 48 (8.5) | 56 (9.9) | 137(24.3) | 89(15.8) | 23(4.1) | 32(5.7) | 0 |
| 死亡组 | 9(47.4) | 7(36.8) | 2(10.5) | 5(26.3) | 9(47.4) | 9(47.4) | 0 | 1(5.3) | 8(42.1) |
| Z(χ2)值 | 30.697a | 0.487a | 0.094a | 5.268a | 5.164a | 12.990a | 0.808a | 0.082a | 0.273a |
| P值 | <0.001 | 0.485 | 0.760 | 0.022 | 0.023 | <0.001 | 0.369 | 0.775 | 0.601 |
| 组别 | 肺源性心脏病〔例(%)〕 | 冠心病〔例(%)〕 | 心率〔M(P25,P75),次/min〕 | 平均动脉压〔M(P25,P75),mmHg〕 | 呼吸频率〔M(P25,P75),次/min〕 | 体温〔M(P25,P75),℃〕 | |||
| 生存组 | 7(1.2) | 411(72.9) | 86(74,101) | 97(87,110) | 20.00(19.00,22.00) | 36.30(36.20,36.50) | |||
| 死亡组 | 0 | 12(63.2) | 101(95,104) | 106(81,114) | 20.00(20.00,23.50) | 36.20(36.10,36.85) | |||
| Z(χ2)值 | 0.239a | 0.871a | -2.677 | -1.260 | -1.981 | -0.132 | |||
| P值 | 0.625 | 0.351 | 0.007 | 0.208 | 0.048 | 0.895 | |||
| 组别 | 血红蛋白〔M(P25,P75),g/L〕 | 阴离子间隙〔M(P25,P75),mmol/L 〕 | 尿素氮〔M(P25,P75),mmol/L 〕 | 肌酐〔M(P25,P75),μmol/L〕 | 葡萄糖〔M(P25,P75),mmol/L〕 | 钠〔M(P25,P75),mmol/L〕 | |||
| 生存组 | 129.00(113.00,144.00) | 10.20(8.10,11.80) | 7.41(5.54,11.57) | 84.15 (65.50,122.60) | 6.77(5.28, 9.67) | 138.00(135.00,141.00) | |||
| 死亡组 | 98.00 (86.50,124.50) | 15.90(9.70,19.70) | 28.48(9.66,31.38) | 170.50(110.40,277.60) | 9.70(8.08,14.54) | 141.00(137.50,146.50) | |||
| Z(χ2)值 | -3.262 | -3.752 | -4.258 | -3.437 | -1.404 | -1.073 | |||
| P值 | 0.001 | <0.001 | <0.001 | 0.001 | 0.160 | 0.283 | |||
| 组别 | 钾〔M(P25,P75),mmol/L〕 | 凝血酶原时间〔M(P25,P75),s〕 | 中性粒细胞计数〔M(P25,P75),×109/L〕 | 单核细胞计数〔M(P25,P75),×109/L〕 | 淋巴细胞计数〔M(P25,P75),×109/L〕 | NMLR〔M(P25,P75)〕 | |||
| 生存组 | 3.95(3.57,4.52) | 13.00(11.90,14.30) | 5.52(4.11,7.95) | 0.40(0.37,0.57) | 1.18(0.79,1.66) | 5.00(3.23,8.72) | |||
| 死亡组 | 4.10(3.75,4.41) | 12.90(12.60,16.35) | 6.17(4.34,6.82) | 0.44(0.34,0.62) | 0.89(0.73,1.73) | 8.36(3.15,9.55) | |||
| Z(χ2)值 | -0.933 | -1.641 | -2.860 | -1.369 | -2.005 | -3.089 | |||
| P值 | 0.351 | 0.101 | 0.004 | <0.001 | 0.045 | 0.002 |
| 项目 | 单因素分析 | 多因素分析 | ||
|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | |
| 感染 | 2.614(1.020,6.698) | 0.045 | 1.133(0.760,1.690) | 0.539 |
| 糖尿病 | 2.003(0.789,5.080) | 0.144 | ||
| 肺循环障碍 | 6.326(2.460,12.267) | <0.001 | 0.954(0.544,1.672) | 0.869 |
| 周围血管病 | 3.346(1.177,9.515) | 0.023 | 0.958(0.571,1.608) | 0.872 |
| 脑血管病 | 2.305(0.918,5.786) | 0.075 | ||
| 肾衰竭 | 3.766(1.514,9.370) | 0.004 | 0.937(0.577,1.522) | 0.794 |
| 心率 | 1.026(1.006,1.047) | 0.013 | 0.995(0.986,1.004) | 0.306 |
| 呼吸频率 | 1.039(0.993,1.087) | 0.097 | ||
| 血红蛋白 | 0.969(0.955,0.93) | <0.001 | 0.993(0.986,1.000) | 0.042 |
| 阴离子间隙 | 1.246(1.143,1.358) | <0.001 | 1.062(1.009,1.118) | 0.021 |
| 尿素氮 | 1.094(1.060,1.129) | <0.001 | 1.011(0.985,1.036) | 0.413 |
| 肌酐 | 1.000(1.000,1.001) | 0.318 | ||
| 中性粒细胞 | 1.034(1.009,1.059) | 0.007 | 1.098(1.031,1.170) | 0.004 |
| 单核细胞 | 1.342(1.125,1.602) | 0.001 | 1.338(1.092,1.639) | 0.005 |
| 淋巴细胞 | 0.578(0.435,0.768) | <0.001 | 0.560(0.410,0.765) | <0.001 |
| NMLR | 1.026(1.007,1.046) | 0.008 | 1.003(1.001,1.005) | 0.028 |
Table 2 Univariate and multivariate Cox analysis of influencing factors of in-hospital mortality in patients with HF
| 项目 | 单因素分析 | 多因素分析 | ||
|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | |
| 感染 | 2.614(1.020,6.698) | 0.045 | 1.133(0.760,1.690) | 0.539 |
| 糖尿病 | 2.003(0.789,5.080) | 0.144 | ||
| 肺循环障碍 | 6.326(2.460,12.267) | <0.001 | 0.954(0.544,1.672) | 0.869 |
| 周围血管病 | 3.346(1.177,9.515) | 0.023 | 0.958(0.571,1.608) | 0.872 |
| 脑血管病 | 2.305(0.918,5.786) | 0.075 | ||
| 肾衰竭 | 3.766(1.514,9.370) | 0.004 | 0.937(0.577,1.522) | 0.794 |
| 心率 | 1.026(1.006,1.047) | 0.013 | 0.995(0.986,1.004) | 0.306 |
| 呼吸频率 | 1.039(0.993,1.087) | 0.097 | ||
| 血红蛋白 | 0.969(0.955,0.93) | <0.001 | 0.993(0.986,1.000) | 0.042 |
| 阴离子间隙 | 1.246(1.143,1.358) | <0.001 | 1.062(1.009,1.118) | 0.021 |
| 尿素氮 | 1.094(1.060,1.129) | <0.001 | 1.011(0.985,1.036) | 0.413 |
| 肌酐 | 1.000(1.000,1.001) | 0.318 | ||
| 中性粒细胞 | 1.034(1.009,1.059) | 0.007 | 1.098(1.031,1.170) | 0.004 |
| 单核细胞 | 1.342(1.125,1.602) | 0.001 | 1.338(1.092,1.639) | 0.005 |
| 淋巴细胞 | 0.578(0.435,0.768) | <0.001 | 0.560(0.410,0.765) | <0.001 |
| NMLR | 1.026(1.007,1.046) | 0.008 | 1.003(1.001,1.005) | 0.028 |
| 变量 | 灵敏度 | 特异度 | 约登指数 | 最佳截断值 | P值 | AUC | 95%CI |
|---|---|---|---|---|---|---|---|
| NMLR | 0.508 | 0.820 | 0.328 | 7.93 | <0.001 | 0.704 | (0.652,0.757) |
| 单核细胞计数 | 0.234 | 0.932 | 0.166 | 0.76×109/L | 0.003 | 0.585 | (0.525,0.646) |
| 中性粒细胞计数 | 0.492 | 0.719 | 0.211 | 6.15×109/L | <0.001 | 0.620 | (0.563,0.676) |
| 淋巴细胞计数 | 0.002 | 0.999 | 0.001 | 8.93×109/L | <0.001 | 0.341 | (0.289,0.393) |
Table 3 The predictive value of blood cell count indexes for predicting in-hospital mortality in patients with HF
| 变量 | 灵敏度 | 特异度 | 约登指数 | 最佳截断值 | P值 | AUC | 95%CI |
|---|---|---|---|---|---|---|---|
| NMLR | 0.508 | 0.820 | 0.328 | 7.93 | <0.001 | 0.704 | (0.652,0.757) |
| 单核细胞计数 | 0.234 | 0.932 | 0.166 | 0.76×109/L | 0.003 | 0.585 | (0.525,0.646) |
| 中性粒细胞计数 | 0.492 | 0.719 | 0.211 | 6.15×109/L | <0.001 | 0.620 | (0.563,0.676) |
| 淋巴细胞计数 | 0.002 | 0.999 | 0.001 | 8.93×109/L | <0.001 | 0.341 | (0.289,0.393) |
| [1] |
Writing Committee Members,ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure[J]. J Card Fail,2022,28(5):e1-167. DOI:10.1016/j.cardfail.2022.02.010.
|
| [2] |
王华,李莹莹.慢性心力衰竭加重患者的综合管理中国专家共识2022[J].中国循环杂志,2022,37(3):215-225.
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789. DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
唐超,雍莉,刘火五沙,等. 中性粒细胞与淋巴细胞比值与心力衰竭合并心房颤动患者疾病严重程度相关性分析[J]. 临床急诊杂志,2018,19(5):283-287. DOI:10.13201/j.issn.1009-5918.2018.05.002.
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
| [1] | YUAN Yujuan, TAO Jing, WANG Ying, PENG Hui, YANG Yining. Elevated Neutrophil Percentage to Albumin Ratio is Associated with In-hospital Outcomes in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2026, 29(18): 2489-2497. |
| [2] | LI Shilong, WANG He, ZHOU Xiaoyu, FU Lei, ZHAO Zhuo, HUA Chengjun, SI Chunying. Advances in the Study of Cardiac Macrophages in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2026, 29(15): 2084-2091. |
| [3] | LI Jiali, LIU Fan, KE Lixin, LI Huijuan, WANG Haibo, ZHAO Xiaoxiao, ZHAO Xinke, LU Cuncun. Disease Burden of Obesity among Individuals Aged 60 and above Globally and in China from 1990 to 2021: Trend Analysis and Model-based Projection [J]. Chinese General Practice, 2026, 29(15): 2067-2076. |
| [4] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| [5] | QIU Yanli, GAO Yongyin, BIAN Xueyan, WANG Xue, LI Yue. The Predictive Value of Estimated Pulse Wave Velocity for All-cause and Cardiovascular-related Mortality in Cancer Patients [J]. Chinese General Practice, 2026, 29(14): 1890-1897. |
| [6] | WANG Yiheng, XU Xiaoming, XIA Yunlong, XIA Linying, HAN Xue, GUO Yongzhen, LIU Quanchi, YAN Wenjun. Progress in Pharmacotherapy of Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2026, 29(03): 403-408. |
| [7] | JIANG Xiaorui, YAN Yuyao, WEI Jingjing, QIAO Lijie, PENG Guangcao, ZHU Mingjun. Systematic Review of Risk Prediction Models for Concurrent Heart Failure with Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(03): 393-402. |
| [8] | CHEN Xueqin, WANG Shihong, LAI Fengxia, ZHANG Jingjing, CHEN Hao, KONG Danli, DING Yuanlin. Study on Trend Analysis and Forecast of Incidence, Disease and Mortality of Chronic Obstructive Pulmonary Disease in China, 1990-2021 [J]. Chinese General Practice, 2026, 29(02): 264-272. |
| [9] | YANG Qinghui, HU Yingxue, NI Pingwei, LIU Xiao. Analysis of the Incidence and Mortality Trends of Lung Cancer in China from 1990 to 2021 and Prediction for 2035 [J]. Chinese General Practice, 2026, 29(02): 256-263. |
| [10] | MI Lingyu, CHEN Lianxin, GAO Hengbo, WANG Bincheng. Predictive Value of Triglyceride-glucose Index for Prognosis in Patients with Pulmonary Embolism [J]. Chinese General Practice, 2025, 28(35): 4421-4429. |
| [11] | LIU Yongcheng, LIU Siyu, LIANG Xiaoyu, HAO Xiaopeng, WEI Yue, DONG Guoju. Analysis of Echocardiographic Outcome Measures in Randomized Controlled Trials in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(33): 4140-4147. |
| [12] | LIU Mingbo, HE Xinye, YANG Xiaohong, WANG Zengwu. Interpretation of Report on Cardiovascular Health and Diseases in China 2024 [J]. Chinese General Practice, 2025, 28(32): 3989-4008. |
| [13] | ZHANG Ji, ZHOU Jie, LI Ling, WU Yanli, JI Wei, LIU Tao. Associations of Fasting Blood Glucose with All-cause Mortality and Specific-cause Mortality in a Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(31): 3924-3931. |
| [14] | MA Shuangshuang, XING Yanjiang, ZHANG Jiawei, WANG Jing. Research Progress on Cardiac Energy Metabolic Changes in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(30): 3831-3840. |
| [15] | DENG Jie, QI Qi, WU Xinyu, HAN Quanle, LI Lei, JIANG Yue, YU Jing, WU Ruojie, WU Shouling, LI Kangbo. Cohort Study on the Association between the Atherogenic Index of Plasma and the Risk of Incident Heart Failure in a Physical Examination Population [J]. Chinese General Practice, 2025, 28(29): 3645-3652. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||